Cadrenal Therapeutics Common Stock Statistics Share Statistics Cadrenal Therapeutics Common Stock has 2.05M
shares outstanding. The number of shares has increased by 84.28%
in one year.
Shares Outstanding 2.05M Shares Change (YoY) 84.28% Shares Change (QoQ) 4.63% Owned by Institutions (%) n/a Shares Floating 1.38M Failed to Deliver (FTD) Shares 523 FTD / Avg. Volume 1.82%
Short Selling Information The latest short interest is 20.27K, so 1.03% of the outstanding
shares have been sold short.
Short Interest 20.27K Short % of Shares Out 1.03% Short % of Float 1.38% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.66 and the forward
PE ratio is -2.45.
Cadrenal Therapeutics Common Stock's PEG ratio is
0.18.
PE Ratio -1.66 Forward PE -2.45 PS Ratio 0 Forward PS n/a PB Ratio 2.38 P/FCF Ratio -2.4 PEG Ratio 0.18
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cadrenal Therapeutics Common Stock.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.77,
with a Debt / Equity ratio of 0.
Current Ratio 3.77 Quick Ratio 3.77 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.66M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 62.42% in the
last 52 weeks. The beta is 0.95, so Cadrenal Therapeutics Common Stock's
price volatility has been higher than the market average.
Beta 0.95 52-Week Price Change 62.42% 50-Day Moving Average 12.29 200-Day Moving Average 15.42 Relative Strength Index (RSI) 48.43 Average Volume (20 Days) 28,679
Income Statement
Revenue n/a Gross Profit n/a Operating Income -10.96M Net Income -10.65M EBITDA -10.65M EBIT -10.65M Earnings Per Share (EPS) -8.73
Full Income Statement Balance Sheet The company has 10.02M in cash and 0 in
debt, giving a net cash position of 10.02M.
Cash & Cash Equivalents 10.02M Total Debt n/a Net Cash n/a Retained Earnings -25.72M Total Assets 7.95M Working Capital 6.1M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -7.36M
and capital expenditures -6.54K, giving a free cash flow of -7.36M.
Operating Cash Flow -7.36M Capital Expenditures -6.54K Free Cash Flow -7.36M FCF Per Share -6.04
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CVKD does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CVKD is $32,
which is 198.5% higher than the current price. The consensus rating is "Buy".
Price Target $32 Price Target Difference 198.5% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 20, 2024. It was a
backward
split with a ratio of 1:15.
Last Split Date Aug 20, 2024 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -2.6 Piotroski F-Score 0
